scholarly journals Resistant Hypertension, Patient Characteristics, and Risk of Stroke

PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e104362 ◽  
Author(s):  
Chen-Ying Hung ◽  
Kuo-Yang Wang ◽  
Tsu-Juey Wu ◽  
Yu-Cheng Hsieh ◽  
Jin-Long Huang ◽  
...  
Hypertension ◽  
2017 ◽  
Vol 70 (suppl_1) ◽  
Author(s):  
Badhma Valaiyapathi ◽  
Mohammed Siddiqui ◽  
Suzanne Oparil ◽  
David A Calhoun ◽  
Tanja Dudenbostel

Background: Serum uric acid (sUA) levels have been found to be positively associated with increased risk of hypertension (HTN), independent of other cardiovascular risk factors. The role of sUA elevation in patients with resistant hypertension (RHTN) is unknown. We hypothesized that sUA levels are higher in RHTN patients compared to patients with controlled HTN. Methods: This retrospective study included, 140 patients from the University of Alabama at Birmingham Hypertension Clinic. Patient characteristics including body mass index (BMI), office blood pressure (BP) and sUA levels were analyzed. RHTN was defined as office BP > 140/90 mmHg on ≥ 3 or more different antihypertensive agents including a diuretic. Patients with RHTN were compared with a control group with controlled hypertension. Patients with sUA levels <3 mg/dl, who were on treatment with allopurinol, and those with missing values were excluded from the study. Results: Patient characteristics of 91 included patients were: 53.4% female, 40.7% African American, mean age 58.8 ± 12.4 years, mean BMI 33.1 ± 7.5 kg/m 2 , mean sUA 6.6 ± 1.9 mg/dL. Mean sUA was higher among RHTN patients compared to the control group (p = 0.0031). Treatment resistance was found to be strongly correlated with sUA levels of ≥ 6 mg/dl (p = 0.0065). Conclusion: In this retrospective study, sUA levels were found to be significantly higher among resistant HTN patients compared to controlled HTN patients, indicating that high sUA levels (≥ 6 mg/dl) may play a role in treatment resistance among hypertensive patients.


2021 ◽  
Vol 39 (Supplement 1) ◽  
pp. e355
Author(s):  
Joris Vanparys ◽  
Maite Deblaton ◽  
Beatrice Van Frachen ◽  
Axel Derwa

2017 ◽  
Vol 26 (3) ◽  
pp. 133-138 ◽  
Author(s):  
Julian E. Mariampillai ◽  
Per Anders Eskås ◽  
Sondre Heimark ◽  
Anne Cecilie K. Larstorp ◽  
Fadl Elmula M. Fadl Elmula ◽  
...  

2018 ◽  
Vol 15 (3) ◽  
pp. 11-13 ◽  
Author(s):  
A V Aksenova ◽  
T E Esaulova ◽  
O A Sivakova ◽  
I E Chazova

Refractory hypertension is a novel phenotype of antihypertensive treatment failure. The terms "refractory hypertension" and "resistant hypertension" were considered interchangeable for a long time and related to difficult-to-treat hypertension. Recently, the term "refractory hypertension" refers to a very small group of patients who do not really reach the target blood pressure for maximum antihypertensive therapy. In this review we discuss similarities and contrasts definition, prevalence, patient characteristics, risk factors, and possible underlying etiologies of refractory and resistant hypertension.


Sign in / Sign up

Export Citation Format

Share Document